AHA: Amarin's Vascepa halts progression of arterial plaque in key study

18th November 2019 Uncategorised 0

PHILADELPHIA—With an FDA decision to expand Amarin’s Vascepa label to include cardiovascular risk reduction looming, a new imaging study shows the drug could have an effect on stopping the progression of plaque in the arteries. That could help explain Vascepa’s game-changing CV outcomes.

More: AHA: Amarin's Vascepa halts progression of arterial plaque in key study
Source: fierce